Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00609869 · ClinicalTrials.gov registry record · Phase 2

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

A Phase 2 study of Mantle Cell Lymphoma and Lymphocytic Leukemia, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target
2
Study locations

NCT00609869 is a Phase 2 study of Mantle Cell Lymphoma and Lymphocytic Leukemia that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 29 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00609869, a Phase 2 study of Mantle Cell Lymphoma and Lymphocytic Leukemia, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research is to evaluate the use of Rituximab in combination with Revlimid in the treatment of refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). Revlimid® is a drug that changes the immune system and it may also get in the way with the growth of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Revlimid® is approved by the Food and Drug Administration (FDA) for the treatment of specific types of Myelodysplasia syndrome (MDS) and Multiple Myeloma, two different types of blood cancer. It is currently being tested in a variety of cancer conditions. In this case it is considered experimental.

Conditions Studied

Mantle Cell Lymphoma Lymphocytic Leukemia

Interventions

  • DRUG Rituximab
  • DRUG Lenalidomide

Study Locations (2)

Florida

  • Center for Cancer Care & Research/Watson - Lakeland
  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2007-10
Est. Completion 2015-08
Phase Phase 2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00609869

The ClinicalTrials.gov registry entry for NCT00609869 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (72% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.

NCT00609869 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT00609869 about?

NCT00609869 is a clinical study titled "Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab". The purpose of this research is to evaluate the use of Rituximab in combination with Revlimid in the treatment of refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). Revlimid® is a drug that changes the immune system and it may also get in the way with the growth of tiny bl...

What is the current status of trial NCT00609869?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-10. Estimated completion is 2015-08.

What conditions does trial NCT00609869 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma, Lymphocytic Leukemia.

What interventions are being tested in trial NCT00609869?

The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG).

Who is sponsoring clinical trial NCT00609869?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00609869 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

Lymphocytic Leukemia

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.